Domov › Kronična limfocitna levkemija › New York › New York City
Klinične študije za Kronična limfocitna levkemija v New York City, NY
18 študij za Kronična limfocitna levkemija išče udeležence na lokacijah v New York City in okolici (v razdalji približno 30 milj). Odprite študijo, da vidite, kdo lahko sodeluje in kako kontaktirati ekipo.
Uradno besedilo študije (angleško)
Iščete udeležence za študijo? Predstavite jo na vrhu te strani — $99 za 30 dni →
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
Vključevanje udeležencevFaza 1/2
- Columbia University Medical Center, New York
- Weill Cornell Medical College Newyork Presbyterian Hospital, New York
- Memorial Sloan Kettering Cancer Center Mskcc, New York
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Vključevanje udeležencevOpazovalna študijaVabljeni zdravi prostovoljci
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
Vključevanje udeležencevFaza 3
- Memorial Sloan Kettering Cancer Center, New York
A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
Vključevanje udeležencevFaza 1/2
- Research Site, New York
- Research Site, New York
A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
Vključevanje udeležencevFaza 3
- Memorial Sloan Kettering Cancer Center Mskcc, New York
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
Vključevanje udeležencevFaza 3
- Columbia University Medical Center, New York
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
Vključevanje udeležencevFaza 3
- Memorial Sloan Kettering Cancer Center Mskcc, New York
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Vključevanje udeležencevFaza 3
- Columbia University Medical Center, New York
- Weill Cornell Medical College Newyork Presbyterian Hospital, New York
- Memorial Sloan Kettering Cancer Center Mskcc, New York
A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Vključevanje udeležencevFaza 4
- Memorial Sloan-Kettering Cancer Center (MSKCC) - New York, New York
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
Vključevanje udeležencevFaza 3
- David H. Koch Center for Cancer Care, New York
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
Vključevanje udeležencevFaza 1/2
- Research Site, New York
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
Vključevanje udeležencevFaza 1
- Columbia University Irving Medical Center/New York Presbyterian Hospital, New York
Zanubrutinib, Obinutuzumab, Sonrotoclax (BOSon) or BGB-16673, Obinutuzumab, Sonrotoclax (DOSon) in TN CLL/SLL
Vključevanje udeležencevFaza 2
- Memorial Sloan Kettering Cancer Center, New York
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Vključevanje udeležencevFaza 3
- Icahn School of Medicine at Mount Sinai /ID# 266328, New York
Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, LonGEVity Trial
Vključevanje udeležencevFaza 2
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
Vključevanje udeležencevFaza 4
- Memorial Sloan-Kettering Cancer Center (MSKCC) - New York, New York
- Memorial Sloan-Kettering Cancer Center (MSKCC) - New York, New York
- Memorial Sloan-Kettering Cancer Center (MSKCC) - New York, New York
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
Vključevanje udeležencevFaza 4
- Memorial Sloan-Kettering Cancer Center (MSKCC) - New York, New York
Study of SGR-1505 in Mature B-Cell Neoplasms
Vključevanje udeležencevFaza 1
- Weill Cornell, New York
Študije za Kronična limfocitna levkemija v drugih mestih
- Boston, MA31 študij
- Columbus, OH28 študij
- Durham, NC27 študij
- Washington, DC22 študij
- Seattle, WA20 študij
- Rochester, MN18 študij
- Houston, TX17 študij
- Baldwin Park, CA16 študij
- Milwaukee, WI15 študij
- Chicago, IL14 študij
- Cincinnati, OH14 študij
- Nashville, TN13 študij
Druge študije v New York City
- Rak dojke136 študij
- Nemalicelični pljučni rak121 študij
- Rak (vse vrste)109 študij
- Rak prostate103 študij
- Metastatski rak93 študij
- Kolorektalni rak78 študij
- Rak jajčnikov69 študij
- Rak pljuč60 študij
- Množni mielom60 študij
- Rak trebušne slinavke60 študij
- Rak endometrija52 študij
- Akutna mieločna levkemija51 študij
Vir: ClinicalTrials.gov, podatki pridobljeni 6. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.